Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anaptysbio (ANAB) Return on Sales (2016 - 2025)

Anaptysbio (ANAB) has disclosed Return on Sales for 10 consecutive years, with 0.46% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales rose 133.0% year-over-year to 0.46%, compared with a TTM value of 0.06% through Dec 2025, up 243.0%, and an annual FY2025 reading of 0.06%, up 153.0% over the prior year.
  • Return on Sales was 0.46% for Q4 2025 at Anaptysbio, up from 0.3% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.46% in Q4 2025 and bottomed at 32.38% in Q1 2022.
  • Average Return on Sales over 5 years is 9.2%, with a median of 4.34% recorded in 2022.
  • The sharpest move saw Return on Sales tumbled -3123bps in 2021, then surged 2632bps in 2022.
  • Year by year, Return on Sales stood at 30.75% in 2021, then skyrocketed by 86bps to 4.43% in 2022, then fell by -6bps to 4.68% in 2023, then skyrocketed by 81bps to 0.87% in 2024, then surged by 153bps to 0.46% in 2025.
  • Business Quant data shows Return on Sales for ANAB at 0.46% in Q4 2025, 0.3% in Q3 2025, and 1.74% in Q2 2025.